BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
BioNTech (Nasdaq: BNTX) will announce its financial results for Q1 2022 on May 9, 2022. A conference call and webcast for investors and analysts will occur at 8:00 AM EDT (2:00 PM CEST) to report these results and provide a company update. The presentation slides and audio will be accessible via BioNTech's website. They are recognized for their pioneering work in immunotherapy and have multiple collaborations with major pharmaceutical companies, focusing on innovative therapies for cancer and infectious diseases.
- Upcoming financial results announcement may provide insights into growth metrics and guidance.
- Broad portfolio of oncology product candidates and established collaborations with major pharmaceutical companies.
- None.
Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.
The slide presentation and audio of the webcast will be available via this link.
To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:
| United States international: United States domestic (toll-free): Germany: Conference ID: | +1 646 741 3167 +1 877 870 9135 +49 (0) 692 2222 625 3698083 |
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit www.BioNTech.de.
BioNTech Contacts
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
FAQ
When will BioNTech announce its Q1 2022 financial results?
What time is the BioNTech conference call for Q1 2022 results?
Where can I access BioNTech's Q1 2022 financial results presentation?
What is the stock symbol for BioNTech?
What type of therapies does BioNTech focus on?
